Combining immunotherapy with radiation therapy in thoracic oncology

Shahed N. Badiyan  
*University of Maryland at Baltimore*

Michael C. Roach  
*Washington University School of Medicine in St. Louis*

Michael D. Chuong  
*Baptist Health South Florida*

Stephanie R. Rice  
*University of Maryland at Baltimore*

Nasarachi E. Onyeuku  
*University of Maryland at Baltimore*

*See next page for additional authors*

Follow this and additional works at: [https://digitalcommons.wustl.edu/open_access_pubs](https://digitalcommons.wustl.edu/open_access_pubs)

Recommended Citation

https://digitalcommons.wustl.edu/open_access_pubs/7542

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact engeszer@wustl.edu.
Combining immunotherapy with radiation therapy in thoracic oncology

Shahed N. Badiyan¹, Michael C. Roach², Michael D. Chuong³, Stephanie R. Rice¹, Nasarachi E. Onyeuku¹, Jill Remick¹, Srinivas Chilukuri⁴, Erica Glass¹, Pranshu Mohindra¹, Charles B. Simone II¹

¹University of Maryland School of Medicine, Baltimore, MD, USA; ²Washington University School of Medicine, St Louis, MO, USA; ³Miami Cancer Institute at Baptist Health South Florida, Miami, FL, USA; ⁴Apollo Proton Cancer Center, Chennai, India

Abstract: Thoracic malignancies comprise some of the most common and deadly cancers. Immunotherapies have been proven to improve survival outcomes for patients with advanced non-small cell lung cancer (NSCLC) and show great potential for patients with other thoracic malignancies. Radiation therapy (RT), an established and effective treatment for thoracic cancers, has acted synergistically with immunotherapies in preclinical studies. Ongoing clinical trials are exploring the clinical benefits of combining RT with immunotherapies and the optimal manner in which to deliver these complementary treatments.

Keywords: Radiation therapy (RT); immune checkpoint inhibitors (ICIs); immunotherapy; lung cancer; mesothelioma; esophageal cancer; thymoma

Submitted May 02, 2018. Accepted for publication May 08, 2018.
doi: 10.21037/jtd.2018.05.73
View this article at: http://dx.doi.org/10.21037/jtd.2018.05.73

Introducing

Thoracic malignancies, consisting predominantly of non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), have a predilection for distant metastasis and are associated with a poor prognosis (1). Similar outcomes are seen in other cancers of the thorax including malignant pleural mesothelioma (MPM) (2), advanced esophageal cancers (3), advanced stage thymoma, and thymic carcinoma (4). Clearly, novel therapies are needed for these patients to improve tumor control and survival.

In recent years the benefit of immunotherapy, which harnesses the body’s ability to eliminate cancer cells, has emerged for some patients with thoracic malignancies. In fact, the influence of immunotherapy has been so profound that Science magazine named immunotherapy as the “Breakthrough of the Year” in 2013 (5), and it is now considered to be the fourth pillar of cancer care (6). The spotlight has focused especially on immune checkpoint inhibitors (ICIs) (7,8), although other types of immunotherapies including tumor vaccines and chimeric antigen receptor (CAR) T-cell therapy are also promising (9,10).

While immunotherapy alone has shown impressive results in patients with NSCLC beyond what is achievable with conventional therapies, the majority of patients will not achieve such responses. In fact, immunotherapy monotherapy is expected to result in significant benefits for only a subset of patients, especially those with high tumor mutational burden (11). Fortunately, emerging data demonstrate anti-tumor effects may increase with the use of immunotherapy in combinatorial regimens, including dual immune checkpoint blockade (12,13) as well as immunotherapy plus local tumor treatment such as...
While radiation has direct cytotoxic effects on cancer cells, it is well established that RT is capable of generating a robust anti-tumor immune response through effects on the tumor and the tumor microenvironment via a variety of mechanisms including enhanced tumor antigen presentation and upregulated major histocompatibility complex (MHC) class I expression (15). An abundance of preclinical studies demonstrates that radiation combined with checkpoint blockade results in a synergistic effect (16). While the optimal combination in cancer patients remains unclear, there are emerging clinical outcomes data suggesting that RT may, in fact, have systemic effects that go far beyond the locally irradiated target (17,18).

Herein, we review the preclinical data and clinical outcomes that support the use of radiation and immunotherapy for patients with thoracic malignancies. We also discuss ongoing clinical trials that aim to further expand our understanding of how this treatment combination may further improve the therapeutic index for these patients.

**Preclinical rationale for combining radiation with ICIs**

*The tissue microenvironment (TME) of the lung*

The TME is a complex interplay of neutrophils, T-regulatory cells (Tregs), and myeloid-derived suppressor cells (MDSCs). There are pattern recognition receptors expressed by epithelial cells that can recognize and respond to pathogens through various pathways, as well as kill pathogens via these mechanisms (19,20). The ratio of specific subtypes of immune cells has been shown to be associated with survival in NSCLC, with inactivated mast cells, inactivated CD4+ memory T-cells, and naïve and memory B cells and plasma cells having favorable prognosis in adenocarcinomas; whereas higher abundance of myeloid populations and activated CD4+ memory T-cells are associated with poor prognosis in squamous cell carcinomas (21). Many studies evaluating various interactions of these immune cells have been performed, and overall the tumor assisted macrophages (TAMs), neutrophils, MDSCs, and Tregs all play a role in the TME, with increased T-cell infiltration into tumor, mature dendritic cells, and B cells correlating with favorable prognosis (22).

**RT and immune cell response**

RT has immunomodulation features within the lung parenchyma that can elicit contradictory host responses. RT can beneficially enhance recognition of tumor antigens by augmenting the immune system’s response to the tumor via increased MHC class I expression (23). RT has also been shown to increase levels of transforming growth factor-beta (TGF-β), which can increase Treg representation after RT (24), resulting in a decrease in the response to therapy. RT also recruits MDSCs and macrophages, which in the presence of TGF-β can become M2 polarized and promote tumor growth, invasion and metastasis (25).

Other preclinical work focusing on the immune response of varying RT fractionation schemes shows a difference in immune cell recruitment with fractionation, noting more CD8+ recruitment in higher dose-per-fraction (30 Gy in 1 fraction) schemes compared to more MDSC recruitment with more fractionated approaches (3 Gy x10 fractions) (26-28). As a result of the varying ways that RT can influence the immune system, clinical responses have been mixed.

**Rationale for the combination of ICIs and RT**

The two most actively studied immune-checkpoint receptors are both inhibitory receptors: cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) and programmed cell death protein 1 (PD-1). In general, inhibitory ligands and receptors that regulate T-cell effector functions are overexpressed on tumor cells, while co-stimulatory receptors that regulate T-cell activation are not overexpressed (29). One of the most common mechanisms of immune checkpoint blockade is antibodies to the PD-1 receptor. The role of PD-1 is to limit the activity of T-cells in peripheral tissues at the time of an inflammatory response to infection in order to minimize autoimmunity (30-36). However, in the TME, this process can result in effective immune resistance (37-39).

Inhibition of this checkpoint affects membrane proteins that are located on a range of cells including T-cells, B cells, natural killer (NK) cells, activated monocytes, and dendritic cells (36). Tumor cells frequently express the ligand programmed death-ligand 1 (PD-L1) on their surface, which when bound by PD-1, downregulate antigen receptor signaling resulting in decreased T-cell proliferation and cytokine production, limiting the activity of effector cells (40). Additionally, PD-1 has been found to be overstimulated and tumor-specific on T-cells (41). Increased expression of PD-L1 has been shown to result in lower numbers of tumor infiltrating lymphocytes (TILs) (42), and
higher expression of PD-L1 on tumor cells has been shown to correlate with better response to PD-1 antibody therapy (43).

The second most common checkpoint inhibitor is targeted to a receptor on T-cells known as CTLA-4, which has a high affinity for Tregs. Through its binding interaction with CD80 and CD86 (which limits binding of these to CD28) on antigen presenting cells (APCs), it both promotes Treg immunosuppressive function and sends inhibitory signaling to T-cells (29). With the greater affinity of binding of CTLA-4 to CD80 and CD86 over CD28, there is a negative feedback loop that leads to T-cell activation and increased CTLA-4 expression in order to prevent autoimmune reactions (44). Finally, murine models have demonstrated that the primary mode of action of anti-CTLA-4 drugs is primarily by depleting Tregs via antibody-dependent cell-mediated cytotoxicity (45).

Based on the promising preclinical data combining RT and immune checkpoint blockers for non-thoracic malignancies, a number of investigators have explored the efficacy of the combination in preclinical NSCLC models. An initial study of KRAS-mutant NSCLC showed improved survival and tumor shrinkage when combining RT and an anti-PD-1 antibody compared to either modality alone (46). Studies have indicated that this synergy may be the result of RT overcoming PD-1 inhibitor resistance via induction of type I interferon (IFN) production leading to enhanced MHC class 1 expression (47). This combination may be promising for translation into the clinic for patients who initially become resistant to anti-PD-1 therapy as a way to increase responsiveness to therapy.

CTLA-4 blockade has also been studied in preclinical lung cancer mouse models in combination with RT (48). Yoshimoto et al. found that RT alone doubled median survival, and the addition of anti-CTLA-4 antibody increased the anti-tumor activity of RT by prolonging the tumor growth delay from 13.1 to 19.5 days. Another study combining RT with anti-CD25 therapy led to decreased Tregs in the spleen and the tumor when compared to monotherapy in an LL/C mouse model (49).

Preclinical studies have also demonstrated potential synergetic effects when combining RT with ICIs. PD-1 blockade enhances T-cells, driving immune response and increasing effector cell activity, while CTLA-4 blockade depletes inhibitory Tregs (50). Additionally, RT alone can influence the immune system in a multitude of ways, some of which enhance tumor response while others render further RT less effective. However, the combination of RT and immune checkpoint blockade has the ability to enhance effects of either one of these therapies alone (and even overcome ineffectiveness of monotherapy), providing an exciting interdisciplinary approach to the management of NSCLC (51).

**Preclinical rationale for combining radiation with immunotherapy beyond checkpoint inhibitors**

Modulation of ICIs targeting receptors such as CTLA-4 and PD-L1 is backed by compelling data as demonstrated in recent Checkmate trials (52,53). While promising, checkpoint inhibition as a treatment strategy benefits only a limited population of patients. Accordingly, other immunomodulatory techniques have been investigated including the use of T-cells that have been genetically modified to target cancer specific CARs.

**Basic principles of CAR T-cell therapy**

The ability to evade growth suppression and circumvent immunosurveillance is a distinct feature of cancer cells (54). This hallmark characteristic is mediated, in part, by the downregulation of the class 1 MHC proteins. The crux of CAR T-cell therapy is based on genetically engineering a T-cell with a CAR that can recognize cancer cells independent of MHC proteins. While the theory of T-cell mediated therapy is not new, advances in molecular synthesis have elevated this strategy as an exciting therapeutic option (55-58).

Constructing these modified T-cells requires attention to two major components: an intracellular transmembrane component and an extracellular, tumor-recognition component. The development of these genetically engineered T-cells has been characterized by increasingly complex co-stimulatory activation domains within the intracellular component to achieve a sustainable T-cell response. Specifically, the first generation of CAR T-cells contained a CD-3ζ containing domain, while additional domains including CD28, OX40 or 4-1BB now characterize the latest generation of CAR T-cells. Equally, the extracellular component must be designed for a specific target on cancer cells to maximize efficacy while minimizing the potential for “on target, off tumor” effects where non-pathologic tissues are targeted (59).

**Challenges to effective CAR T-cell therapy**

The use of CAR T-cells in solid tumors presents the unique
Preclinical data supporting the use of RT with immunotherapy

Beyond the benefits of direct cytotoxicity, radiotherapy is associated with immunomodulatory effects that can be leveraged in combination with immunotherapy (66). Consequently, this also presents a greater opportunity for targeting specific tumor-associated antigens (23,64,67). Specific examples of radiotherapy-inducing tumor-associated antigens were demonstrated in carcinoembryonic antigen (CEA)- and mesothelin-expressing tumors. Radiotherapy has been shown to upregulate the expression of the Fas gene in CEA-expressing tumor cells. Using a mouse model, Chakraborty et al. highlighted that radiotherapy enhanced Fas gene expression leading to improved antitumor activity in the setting of CEA-based vaccine therapy where T-cell killing proceeds through the Fas/FasL pathway (68). Mesothelin is a cell surface protein overexpressed in mesotheliomas, pancreatic, and ovarian tumors (69). Hassan et al. demonstrated the dose-dependent response of irradiated A4310K5 carcinoma cells resulting in elevated extracellular mesothelin expression and enhanced antitumor activity of an anti-mesothelin immunotoxin against mesothelin-expressing tumor xenografts. Additional examples of increased tumor associated antigens following radiotherapy include c-met and HER2 (70,71). Beyond enhancing tumor-associated antigens, radiotherapy also has been shown to address some of the barriers to effective T-cell therapy related to trafficking and chemotaxis (72-74).

Preclinical studies demonstrating the treatment synergy between CAR T-cell therapy and radiotherapy are encouraging (75,76). Radiotherapy appears to be a complimentary immunomodulator with the potential to help overcome many of the difficulties surrounding effective CAR T-cell therapy and function beyond its cytotoxic effects. While clinical outcomes of this approach are more limited than combining radiotherapy with ICIs, to further optimize the radiotherapy-CAR T cell combination approach, topics such as the timing of radiation relative to CAR T-cell therapy and the ideal dose and fractionation of radiotherapy will need to be addressed. CART T-cell therapy is currently under investigation for metastatic NSCLC in a phase II clinical trial at the National Institutes of Health (NCT02133196). The combination CAR T-cell therapy and radiation is likely to be explored in future clinical trials that promise to enhance our understanding of this treatment paradigm.

Radiation plus immunotherapy for metastatic NSCLC

More than half of patients with NSCLC present with distant metastases at the time of diagnosis (77). Unfortunately, long-term survival for patients with stage IV NSCLC is rare with 5-year overall survival (OS) less than 5% (77). For patients with stage IV NSCLC, RT has historically been used only for palliative purposes and has not been thought to improve survival over chemotherapy alone. However, two recent randomized clinical trials have demonstrated that in appropriately selected NSCLC patients with a low burden of metastatic disease to a limited number of distant sites (oligometastatic), RT can improve progression-free survival (PFS) and potentially OS (78,79). This revelation, along with the preclinical findings of the potential synergy of RT with immunotherapies has opened up an exciting new indication for RT in patients with metastatic NSCLC.

Platinum-based doublet chemotherapy has historically been the standard first-line systemic therapy regimen for patients with metastatic NSCLC without activating mutations in epidermal growth factor receptor (EGFR) or translocations in anaplastic lymphoma kinase (ALK) or ROS1 (80). Taxane-based regimens have historically been utilized as second-line regimens for patients that have progressive disease after receiving a platinum-based regimen (81). In 2015, results of the CheckMate 017 trial revolutionized systemic therapy for NSCLC. That trial randomized patients with metastatic NSCLC who had progressed during or after first-line chemotherapy to docetaxel or the PD-1 inhibitor, nivolumab, found a significant improvement in median OS along with
significantly fewer serious treatment-related adverse events (AEs) in the nivolumab arm (52). Similarly, the nearly identical KEYNOTE-010 and POPLAR trials found significant improvements in OS and fewer serious AEs in patients receiving the PD-1 inhibitor pembrolizumab, or the PD-L1 inhibitor atezolizumab, respectively, in patients with metastatic NSCLC that had progressed during or after first-line chemotherapy (82,83). PD-L1 expression ≥1% on tumor cells was required in the KEYNOTE-010 trial. Based on the results of these ground-breaking clinical trials, the FDA approved nivolumab, pembrolizumab, and atezolizumab for second-line treatment of metastatic NSCLC.

Two recent clinical trials have demonstrated that ICIs are also effective as first-line therapy for select patients with metastatic NSCLC. The KEYNOTE-024 trial randomized patients with treatment-naïve metastatic NSCLC without sensitizing EGFR mutations or ALK rearrangements and with PD-L1 expression ≥50% to pembrolizumab or platinum-based chemotherapy. The investigators found that response rate and OS were significantly better in the pembrolizumab group compared to the chemotherapy group and fewer severe AEs occurred in the pembrolizumab group. Based on the results of this trial, the FDA approved pembrolizumab for first-line treatment of patients with metastatic NSCLC whose tumors express PD-L1 on ≥50% of tumor cells (84). The KEYNOTE-189 trial randomized patients with treatment-naïve metastatic non-squamous NSCLC without sensitizing EGFR mutations or ALK rearrangements regardless of PD-L1 expression to a platinum-based chemotherapy doublet with pembrolizumab or the same chemotherapy regimen plus placebo. Patients on the pembrolizumab arm had significantly higher OS and PFS regardless of PD-L1 expression levels, with similar rates of severe AEs (85).

The rapid adoption of ICIs for metastatic NSCLC and the frequent need for palliative RT for this patient population have resulted in a number of retrospective analyses reporting the safety and efficacy of combining ICIs with RT. Hubbeling et al. reported no significant difference in RT-related AEs in patients with metastatic NSCLC receiving cranial RT that previously or concurrently received PD-1/PD-L1 inhibitors compared to patients receiving cranial RT who were PD-1/PD-L1 inhibitor naïve (86). This and other early clinical data indicating that combining RT with ICIs may be safe, and the promising preclinical data demonstrating potential increased efficacy with the combination has led to at least 4 ongoing prospective clinical trials evaluating the safety and efficacy of the combination of RT and PD-1/PD-L1 inhibitors for metastatic NSCLC, and an additional 8 trials combining RT with other immunotherapy agents or combinations of ICIs (Table 1). Many studies are evaluating hypofractionated regimens, usually via stereotactic body radiation therapy (SBRT), rather than lower doses of RT typically used in the palliative setting, in hopes of eliciting greater antigen release in an attempt to improve the efficacy of the ICIs. The results of these clinical trials, expected in the next few years, will greatly enhance our understanding of the potential for RT to synergize with ICIs to provide clinically meaningful improvements in outcomes of patients with metastatic NSCLC.

Radiation plus immunotherapy locally advanced and early stage NSCLC

Locally advanced

Approximately one-quarter of patients with NSCLC present with locally advanced disease with regional lymph node involvement. For years, these patients have been primarily treated with concurrent platinum-based doublet chemotherapy and daily RT over 6 to 7 weeks. However, long-term disease control rates with this approach are limited. Two years after chemoradiation, nearly half of patients develop distant metastases, and only 30% will be alive without progressive disease (87). There were not any major advances in this approach for many years with randomized clinical trials of both induction (88) and maintenance chemotherapy (89) failing to consistently demonstrate improvements in OS. Dose escalation with conventional radiation even seems to decrease OS for patients with locally advanced disease (87).

While there have been other studies looking at vaccines as immunotherapy for patients with locally advanced NSCLC (10,90,91), START (Stimulating Targeted Antigenic Response To non-small-cell lung cancer) was the earliest randomized phase III clinical trial to add immunotherapy consolidation after chemoradiation for locally advanced NSCLC (9). It assessed the efficacy of tecemotide, a mucin 1 (MUC1) antigen-specific liposome vaccine injected subcutaneously. In earlier studies, it was capable of inducing a T-cell response in both mouse models and patients. A single-arm phase 2 trial after chemoradiation showed promising results (92). START enrolled 1,513 patients and randomized them in a 2:1 ratio
<table>
<thead>
<tr>
<th>National clinical trial ID number</th>
<th>Phase</th>
<th>Participating institution(s)</th>
<th>Histology</th>
<th>Stage</th>
<th>Immunotherapy agent</th>
<th>Immunotherapy mechanism of action</th>
<th>Radiation</th>
</tr>
</thead>
<tbody>
<tr>
<td>NCT03110978</td>
<td>II randomized</td>
<td>MD Anderson Cancer Center</td>
<td>NSCLC</td>
<td>I</td>
<td>Nivolumab</td>
<td>PD-1</td>
<td>SBRT</td>
</tr>
<tr>
<td>NCT02599454</td>
<td>I</td>
<td>UC Davis and David Grant United States Air Force Medical Center</td>
<td>NSCLC</td>
<td>I</td>
<td>Atezolizumab</td>
<td>PD-L1</td>
<td>SBRT</td>
</tr>
<tr>
<td>NCT03050554</td>
<td>I/I</td>
<td>UC San Diego</td>
<td>NSCLC</td>
<td>I</td>
<td>Avelumab</td>
<td>PD-L1</td>
<td>SBRT</td>
</tr>
<tr>
<td>NCT03148827</td>
<td>II randomized</td>
<td>UCLA</td>
<td>NSCLC</td>
<td>I</td>
<td>Durvalumab</td>
<td>PD-L1</td>
<td>SBRT</td>
</tr>
<tr>
<td>NCT03446911</td>
<td>II randomized</td>
<td>VU Medical Center</td>
<td>NSCLC</td>
<td>I</td>
<td>Pembrolizumab</td>
<td>PD-1</td>
<td>SBRT</td>
</tr>
<tr>
<td>NCT03383302</td>
<td>II</td>
<td>Multi Center led by Royal Marsden</td>
<td>NSCLC</td>
<td>I–II</td>
<td>Nivolumab</td>
<td>PD-1</td>
<td>SBRT</td>
</tr>
<tr>
<td>NCT02621398</td>
<td>I</td>
<td>Multicenter led by Rutgers Cancer Institute of New Jersey</td>
<td>NSCLC</td>
<td>II–III</td>
<td>Pembrolizumab concurrently with carboplatin and paclitaxel</td>
<td>PD-1</td>
<td>Conventionally fractionated IMRT or 3D-CRT</td>
</tr>
<tr>
<td>NCT02434081</td>
<td>II</td>
<td>European Thoracic Oncology Platform</td>
<td>NSCLC</td>
<td>IIIA–IIIB</td>
<td>Nivolumab concurrently with carboplatin and paclitaxel</td>
<td>PD-1</td>
<td>Conventionally fractionated RT</td>
</tr>
<tr>
<td>NCT03245177</td>
<td>I</td>
<td>University of Manchester</td>
<td>NSCLC</td>
<td>III</td>
<td>Pembrolizumab</td>
<td>PD-1</td>
<td>Conventionally fractionated RT</td>
</tr>
<tr>
<td>NCT03237377</td>
<td>II</td>
<td>Johns Hopkins University</td>
<td>NSCLC</td>
<td>IIIA</td>
<td>Durvalumab/tremelimumab</td>
<td>PD-L1/CTLA-4</td>
<td>Conventionally fractionated RT</td>
</tr>
<tr>
<td>NCT03035890</td>
<td>n/a</td>
<td>West Virginia University</td>
<td>NSCLC</td>
<td>IV</td>
<td>Nivolumab/pembrolizumab/atezolizumab</td>
<td>PD-1/PD-1/PD-L1</td>
<td>Hypofractionated RT</td>
</tr>
<tr>
<td>NCT03509584</td>
<td>I</td>
<td>Assistance Publique Hôpitaux De Marseille</td>
<td>NSCLC</td>
<td>IV</td>
<td>Nivolumab/pilimulub</td>
<td>PD-1/CTLA-4</td>
<td>Hypofractionated RT</td>
</tr>
<tr>
<td>NCT02463994</td>
<td>I</td>
<td>Multicenter let by University of Michigan</td>
<td>NSCLC</td>
<td>IV</td>
<td>Atezolizumab</td>
<td>PD-L1</td>
<td>Hypofractionated RT</td>
</tr>
<tr>
<td>NCT03176173</td>
<td>II</td>
<td>Stanford University</td>
<td>NSCLC</td>
<td>IV</td>
<td>Nivolumab/pembrolizumab/atezolizumab</td>
<td>PD-1/PD-1/PD-L1</td>
<td>Hypofractionated RT</td>
</tr>
<tr>
<td>NCT03313804</td>
<td>II</td>
<td>University of Kentucky</td>
<td>NSCLC</td>
<td>IV</td>
<td>Nivolumab/pembrolizumab/atezolizumab</td>
<td>PD-1/PD-1/PD-L1</td>
<td>SBRT or conventional palliative RT</td>
</tr>
<tr>
<td>NCT02839265</td>
<td>II</td>
<td>Montefiore Medical Center</td>
<td>NSCLC</td>
<td>IV</td>
<td>CDX-301</td>
<td>FLT3 ligand</td>
<td>SBRT</td>
</tr>
<tr>
<td>NCT03168464</td>
<td>I/I</td>
<td>Weill Medical College of Cornell University</td>
<td>NSCLC</td>
<td>IV</td>
<td>Nivolumab/pilimulub</td>
<td>PD-1/CTLA-4</td>
<td>Hypofractionated RT</td>
</tr>
</tbody>
</table>

Table 1 (continued)
<table>
<thead>
<tr>
<th>National clinical trial ID number</th>
<th>Phase</th>
<th>Participating institution(s)</th>
<th>Histology</th>
<th>Stage</th>
<th>Immunotherapy agent(s)</th>
<th>Immunotherapy mechanism of action</th>
<th>Radiation</th>
</tr>
</thead>
<tbody>
<tr>
<td>NCT03275597 Ib</td>
<td>Ib</td>
<td>University of Wisconsin</td>
<td>NSCLC</td>
<td>IV</td>
<td>Durvalumab/tremelimumab</td>
<td>PD-L1/CTLA-4</td>
<td>SBRT</td>
</tr>
<tr>
<td>NCT03223155 I</td>
<td>I</td>
<td>University of Chicago</td>
<td>NSCLC</td>
<td>IV</td>
<td>Nivolumab/pilumumab</td>
<td>PD-1/CTLA-4</td>
<td>SBRT</td>
</tr>
<tr>
<td>NCT03224871 Pilot</td>
<td></td>
<td>UC Davis</td>
<td>NSCLC</td>
<td>IV</td>
<td>IL-2/nivolumab/pembrolizum</td>
<td>IL-2/PD-1/PD-1</td>
<td>Hypofractionated RT</td>
</tr>
<tr>
<td>NCT03391869 III randomized</td>
<td></td>
<td>MD Anderson Cancer Center</td>
<td>NSCLC</td>
<td>IV</td>
<td>Nivolumab/pilumumab</td>
<td>PD-1/CTLA-4</td>
<td>Hypofractionated RT or SBRT</td>
</tr>
<tr>
<td>NCT02221739 II</td>
<td>II</td>
<td>New York University</td>
<td>NSCLC</td>
<td>IV</td>
<td>Ipilimumab</td>
<td>CTLA-4</td>
<td>Hypofractionated RT</td>
</tr>
<tr>
<td>NCT02402920 I</td>
<td>I</td>
<td>MD Anderson Cancer Center</td>
<td>SCLC</td>
<td>Limited and extensive stage</td>
<td>Pembrolizumab with carboplatin and etoposide</td>
<td>PD-1</td>
<td>Hyperfractionated or Hypofractionated RT</td>
</tr>
<tr>
<td>NCT02701400 II randomized</td>
<td>II</td>
<td>Emory University</td>
<td>SCLC</td>
<td>Recurrent</td>
<td>Durvalumab and Tremelimumab</td>
<td>PD-L1 and CTLA-4</td>
<td>Hypofractionated RT and SBRT</td>
</tr>
<tr>
<td>NCT03399552 I/II</td>
<td>I/II</td>
<td>Memorial Sloan Kettering Cancer Center</td>
<td>Malignant pleural mesothelioma</td>
<td>Recurrent</td>
<td>Avelumab</td>
<td>PD-L1</td>
<td>SBRT</td>
</tr>
<tr>
<td>NCT03377400 II</td>
<td>II</td>
<td>Samsung Medical Center</td>
<td>Esophageal squamous cell carcinoma</td>
<td>Inoperable T2–3N0M0 or T1–3N1–3M0</td>
<td>Durvalumab/tremelimumab with 5-Flurouracil and cisplatin</td>
<td>PD-L1/CTLA-4</td>
<td>Conventionally fractionated RT</td>
</tr>
<tr>
<td>NCT03437200 II randomized</td>
<td>II</td>
<td>European Organisation for Research and Treatment of Cancer</td>
<td>Esophageal cancer</td>
<td>Inoperable T1N1–3M0 or T2–3N0–3M0</td>
<td>Nivolumab/pilumumab with FOLFOX</td>
<td>PD-1/CTLA-4</td>
<td>Conventionally fractionated RT</td>
</tr>
<tr>
<td>NCT02642809 I</td>
<td>I</td>
<td>Washington University in St Louis</td>
<td>Esophageal cancer</td>
<td>IV</td>
<td>Pembrolizumab</td>
<td>PD-1</td>
<td>Intracavitary brachytherapy</td>
</tr>
<tr>
<td>NCT02735239 I/II</td>
<td>I/II</td>
<td>Ludwig Institute for Cancer Research</td>
<td>Esophageal cancer</td>
<td>II–IV</td>
<td>Durvalumab/tremelimumab with capecitabine and paclitaxel</td>
<td>PD-L1/CTLA-4</td>
<td>Conventionally fractionated RT</td>
</tr>
</tbody>
</table>

SBRT, stereotactic body radiation therapy; IL-2, interleukin-2; PD-1, programmed cell death protein 1; PD-L1, programmed death1ligand 1; CTLA-4, cytotoxic T-lymphocyte-associated protein 4; FOLFOX, 5-flurouracil, leucovorin, oxaliplatin; RT, radiation therapy; NSCLC, non-small cell lung cancer; SCLC, small cell lung cancer.
to immunotherapy consolidation versus placebo. This trial showed no significant difference in OS for all patients in the modified intention-to-treat population. However, in a subset analysis of patients who received concurrent chemoradiation therapy, median OS was 30.8 months with immunotherapy compared to 20.6 months with placebo (P=0.016). In those who received sequential chemotherapy and RT, however, there was no difference in OS (P=0.38).

Importantly, this drug showed no increase in serious grade 3 or 4 AEs (9).

In a similar study design to START, PACIFIC randomized patients to receive consolidation with the anti-PD-L1 antibody durvalumab (at a dose of 10 mg given intravenously per kilogram of body weight) or placebo every 2 weeks until disease progression or 12 months, whichever occurred first (93). Durvalumab was given 1–42 days after the conclusion of chemotherapy and RT. In a report from a planned interim analysis, the median PFS from randomization was 16.8 months with immunotherapy versus 5.6 months with placebo (HR 0.52, P<0.001). The other primary end-point, OS, has yet to be reported. Secondary end points of response rate, duration of response, and the median time to death or distant metastases were all better with durvalumab. Grade 3 or 4 AEs occurred in 29.9% of patients receiving durvalumab and 26.1% of those receiving placebo. The most common grade 3 or 4 AE was pneumonia at 4.4% with durvalumab and 3.8% with placebo.

Adoption of consolidation with durvalumab has been mixed globally to date with many national health systems awaiting the OS results before considering it standard of care. The above PFS results, however, led to FDA approval of durvalumab in the United States, as well as incorporation as a standard of care in the National Comprehensive Cancer Network guidelines for patients with stage III disease, performance status 0–1, and no disease progression after 2 or more cycles of definitive chemoradiation (94). European Society for Medical Oncology guidelines have not yet incorporated durvalumab into national guidelines. A health technology appraisal on this use of durvalumab is expected to be published in January 2019 by the National Institute for Health and Care Excellence in the United Kingdom.

There are other actively recruiting single-arm trials that are exploring other immunotherapy agents (Table 1). MD Anderson Cancer Center is recruiting to DETERRED, a study exploring the safety of MDPL3280A, a PD-L1 inhibitor, as part of consolidation therapy (NCT02525757). There are two studies ongoing that are moving PD-1 inhibitors earlier in the treatment sequence at the same time as concurrent chemotherapy and RT. In a Rutgers Cancer Institute of New Jersey led multi-center trial, the safety of adding pembrolizumab to carboplatin and paclitaxel for patients with stage II–IIIB NSCLC (NCT02621398) is being tested. A similar phase II study by the European Thoracic Oncology Platform is evaluating pneumonitis rates with the addition of 4 doses of nivolumab given concurrently with standard concurrent chemotherapy (NCT02434081). Both radiation and immunotherapy can cause a similar presentation of pneumonitis, and to date, there are little prospective data on the potential synergistic toxicity of the combination. This combination is, therefore, being approached with caution.

**Early stage**

Patients with NSCLC without regional nodal spread can either undergo a resection or be treated with RT. SBRT has emerged over the past decade as an effective treatment with improved disease control and patient quality of life when compared to conventionally fractionated radiation (95). While primary tumor control is high with SBRT, systemic recurrence remains problematic, and the predominant method of failure. However, SBRT has been shown anecdotally to cause an abscopal effect in patients receiving immunotherapy for a variety of solid tumors, where after the administration of radiation to one location, there is a response in tumor(s) at distant sites. There is hope that this combination in early stage NSCLC can reduce the rate of nodal and distant recurrences. Trials are exploring whether the combination of SBRT with immunotherapy can be performed safely, as patients with early stage NSCLC have longer life expectancies and thus are at risk of developing long-term toxicities.

In the United States, there are at least four clinical trials assessing the efficacy and safety of ICIs after SBRT for early-stage NSCLC (Table 1). A multicenter phase I study of atezolizumab, an anti-PD-L1 monoclonal antibody, in combination with SBRT in high-risk early-stage NSCLC is recruiting (NCT02599454) in order to determine the maximum tolerated dose (MTD) of atezolizumab with SBRT. A similar phase I/II study is recruiting at the University of California, San Diego using the PD-L1 monoclonal antibody, avelumab (NCT03050554), and two separate phase II are randomizing patients with early-stage NSCLC to SBRT with or without durvalumab (NCT03148327) or nivolumab (NCT03110978),
respectively.

In Europe, two trials will explore the tolerability of combining SBRT and PD-1 antibodies (Table 1). Tolerability is largely defined by the rate of grade 3 or greater pneumonitis. At VU University Medical Center in the Netherlands, patients with early stage node-negative NSCLC will be randomized to receive either SBRT alone or SBRT with 2 cycles of pembrolizumab followed by lobectomy (NCT03446911). If the rate of grade 3 or greater pneumonitis is ≤10%, the combination will be regarded as safe. In Great Britain, STILE (NCT03383302) is a single arm, multi-center phase II open-label study of nivolumab given within 24 hours of the final fraction of SBRT then every 2 weeks. If the rate of grade 3 or greater pneumonitis exceeds 20% in the first 6 months, the combination will be deemed unacceptable.

As these small studies attest, combining immunotherapy and RT for early-stage NSCLC is still in its infancy. Challenges with early-stage patients include appropriate selection of the patients that are most likely to benefit from combined modality treatment as well as optimal sequencing and duration of immunotherapy. The optimal radiation dose and fractionation for SBRT alone remain to be determined for peripheral and central tumors, much less when SBRT is combined with immunotherapy. Pseudoprogression after immunotherapy also will likely make assessing response only more challenging based on current RECIST size-based criteria. Nonetheless, there is promising potential synergy between radiation and immunotherapy to reduce systemic failures and improve cure rates in early stage patients (96).

Radiation plus immunotherapy for SCLC

Despite a plethora of clinical trials for patients with SCLC over the last two decades, little progress has been made and patient outcomes remain poor, with OS ranging between 10 and 30 months depending on extent of disease. Although very responsive to first-line chemotherapy, SCLC frequently relapses, and response to second-line agents is extremely poor (97). Immunotherapy has thus been an exciting development for SCLC as it has the potential to overcome the limitations of chemotherapy by targeting SCLC in a novel way.

The advent of immunotherapy has spurred a search for biomarkers that can predict which patients may best respond to ICIs. PD-L1 expression, though helpful, has modest sensitivity and specificity (84). Numerous preclinical and clinical studies have demonstrated that tumors with a high mutagenic burden, and thus high expression of neoantigens, have high response rates to ICIs, irrespective of levels of PD-L1 tumor expression (11). SCLC has long been known to have a high tumor mutation burden (98). This has been found to be correlated with response to checkpoint inhibitors due to re-awakening of pre-existing strong anti-tumor CD8+ cytotoxic T-cell responses (98,99). There is also some pre-clinical and clinical evidence for an immunomodulatory effect of SCLC tumor cells on host immune system (100-102). The higher propensity of paraneoplastic syndromes in SCLC is also hypothesized to be evidence to suggest that several cross-reacting antibodies recruited by the host immune response target both tumor as well as normal cells. Apart from the immuno-stimulatory effects, there is evidence to suggest that SCLC tumor cells also exhibit a regulatory effect through induction of CD4+ Treg cells and decreased expression of HLA-class 1 antigen on host immunity. This balance between the effector and regulatory effects may distinguish extensive stage SCLC (ES-SCLC) from limited stage SCLC (LS-SCLC) (103).

Both single and combination immunotherapy regimens have been investigated in SCLC. The first agent evaluated in ES-SCLC was the CTLA-4 antibody ipilimumab. A number of studies, including a randomized phase III trial evaluating it in combination with chemotherapeutic agents in the first line setting, showed objective responses but failed to meet their primary survival endpoints (104). The KEYNOTE 028 study evaluated pembrolizumab in previously treated ES-SCLC patients. It showed an impressive response rate (RR) of 29% in unselected and 33.3% in PD-L1 expression-positive patients. Responses were rapid and durable with a median duration of response of 19.4 months and OS of 9.7 months. It was tolerated well with an acceptable toxicity profile (105). The CheckMate 032 trial, which compared the combination of nivolumab and ipilimumab with single-agent nivolumab as second-line therapy for ES-SCLC patients, showed a RR of 25%, compared to 11% with nivolumab alone and a near doubling of OS (7.9 vs. 4.1 months, respectively) at the expense of increased toxicity (106).

Although encouraging, priming with chemotherapy alone may generate only subpar neoantigen expression and a subsequent inadequate response. In this context, radiation may enhance tumor immunogenicity by modulating the immune response both at the systemic level and at the level of the tumor microenvironment. There are currently three trials evaluating the combination of radiation with ICIs (Table 1). Investigators at MD Anderson Cancer
Center are performing a phase-I dose escalation study of pembrolizumab in combination with carboplatin, etoposide, and RT in LS-SCLC and ES-SCLC (NCT02402920). In Europe, the ongoing phase II randomized multicenter STIMULI study is comparing standard chemoradiation and prophylactic cranial irradiation followed by either observation alone or 4 cycles of ipilimumab and nivolumab followed by maintenance nivolumab for patients with LS-SCLC (NCT02046733). Finally, Emory University is conducting a randomized phase II study (NCT02701400) evaluating the combination of tremelimumab and durvalumab with or without hypofractionated RT or SBRT in patients with relapsed SCLC. These studies will address the toxicity concerns of combining these agents with radiation, especially in the context of the relatively large target volumes seen in SCLC as well as providing valuable data on the appropriate dose, combination, and timing of the treatments.

Radiation plus immunotherapy for mesothelioma

MPM is a rare disease with poor OS and limited effective treatment options. The development of metastatic disease is common, and there have not been significant strides in cytotoxic chemotherapies in recent years. Patients with MPM often have a large burden of disease and poor performance status, thus the discovery of effective immunotherapies has long been of interest. IL-2, IFN-alfa 2a and IFN-alfa 2b have been evaluated with mixed results (107-109). A recent trial of chemotherapy and adenovirus containing IFN-alfa 2b in previously treated patients has resulted in an encouraging 21.5 months OS (109). Unfortunately, the CTLA-4 inhibitor tremelimumab failed to show an OS benefit in a recent phase III trial (110,111). Anti PD-1/PD-L1 drugs, however, have shown promising results in a series of small studies. Phase-I/II studies incorporating pembrolizumab, nivolumab, and avelumab have shown 9.4–20% partial response rates with stabilization of disease in 50% of patients (112-114). Combined PD-L1 inhibition is also being explored in two ongoing clinical trials (NCT03048474 and NCT02899299). A report from the University of Toronto found that the growth of tumors in a murine mesothelioma model was significantly reduced by hypofractionated radiation and combining radiation with a CTLA-4 inhibitor enhanced the effect in the irradiated and unirradiated tumors (115). Combining radiotherapy and immunotherapy for mesothelioma is a promising treatment strategy (116), and clinical data for the combination of radiation and ICIs are forthcoming. A single arm phase II study has recently been initiated by Memorial Sloan Kettering Cancer Center and will evaluate response rates with Avelumab and SBRT in MPM (NCT03399552) (Table 1).

Radiation plus immunotherapy for esophageal cancer

Trimodality therapy consisting of concurrent chemoradiation followed by surgical resection is the standard of care for locally advanced esophageal cancer patients who are surgical candidates. The 5-year OS with this approach ranges from 39–47% (117,118). In patients that are medically inoperable or have unresectable disease, definitive chemoradiation is recommended; however, survival rates are poor and persistence of locoregional disease occurs in nearly half of patients (119,120). More aggressive treatments such as radiation dose-escalation and the addition of targeted systemic agents against receptors commonly expressed in esophageal cancer such as EGFR have so far failed to improve patient outcomes (120,121).

PD-L1 expression is present in 45% of esophageal cancer tissues and is associated with more locally aggressive disease and decreased survival (122). Irradiated tumors have been associated with an increased expression of PD-L1 leading to suppression of anti-tumoral activity of T-cells (16). Consequently, monoclonal antibodies directed against PD-L1 receptors may act synergistically with RT in killing tumor cells. This is the subject of several ongoing phase I–II trials evaluating safety and efficacy of the combination of chemoradiation with ICIs in both the metastatic/inoperable (NCT03377400, NCT03437200, NCT02642809) and neoadjuvant settings (NCT023735239) (Table 1).

Radiation plus immunotherapy for thymoma

Thymomas represent 20% of all primary mediastinal tumors (123). Surgical resection is the primary treatment. Postoperative radiation is recommended in the presence of positive margins and for advanced stages (4). While survival outcomes are generally good, intrathoracic failures after definitive treatment for thymoma can occur in approximately up to one-quarter of patients (124). Due to its rarity, there is a dearth of understanding of the molecular biology of these tumors, and immunotherapy approaches are limited to small patient cohorts. There are some studies
suggesting PD-L1 expression has higher prevalence in more aggressive histologies (i.e., B1-3 thymomas and thymic carcinomas) and in higher Masaoka stages (125,126). Avelumab was evaluated in 7 patients with locally advanced thymoma and a partial response was observed in 4 of these patients (127). There are two ongoing phase II trials evaluating the efficacy of ICIs in thymomas (NCT02721732 and NCT02607631); however, none currently are in combination with radiation. The efficacy of immunotherapy combined with radiation will likely be of greater interest as our understanding of thymoma tumor biology and its interaction with the immune system improves.

Conclusions

The combination of immunotherapy and RT has the potential to revolutionize treatments for thoracic malignancies. Preclinical data have demonstrated impressive synergy between the two therapies that appears to extend beyond the irradiated target. For patients with advanced NSCLC, recent clinical trials incorporating ICIs have exhibited dramatic improvements in outcomes compared to conventional chemotherapies. We anxiously await results from ongoing and future preclinical research and clinical trials to better define the optimal approaches to combining these two pillars of cancer care.

Acknowledgements

None.

Footnote

Conflicts of Interest: Dr. Badiyan and Dr. Simone have speaker’s honoraria from Varian Medical Systems.

References


